[{"address1": "201 Haskins Way", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 695 0677", "website": "https://lyell.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 224, "auditRisk": 4, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 4, "previousClose": 2.08, "open": 2.08, "dayLow": 2.03, "dayHigh": 2.125, "regularMarketPreviousClose": 2.08, "regularMarketOpen": 2.08, "regularMarketDayLow": 2.03, "regularMarketDayHigh": 2.125, "beta": -0.404, "forwardPE": -2.252747, "volume": 1953795, "regularMarketVolume": 1953795, "averageVolume": 805190, "averageVolume10days": 931140, "averageDailyVolume10Day": 931140, "bid": 2.04, "ask": 2.11, "bidSize": 200, "askSize": 100, "marketCap": 522624960, "fiftyTwoWeekLow": 1.32, "fiftyTwoWeekHigh": 3.41, "priceToSalesTrailing12Months": 7685.661, "fiftyDayAverage": 2.48, "twoHundredDayAverage": 2.079025, "currency": "USD", "enterpriseValue": 58151404, "floatShares": 164219100, "sharesOutstanding": 254939008, "sharesShort": 20104934, "sharesShortPriorMonth": 18226808, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0789, "heldPercentInsiders": 0.154, "heldPercentInstitutions": 0.73245, "shortRatio": 24.99, "shortPercentOfFloat": 0.1121, "impliedSharesOutstanding": 254939008, "bookValue": 2.366, "priceToBook": 0.86644125, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -228340000, "trailingEps": -0.9, "forwardEps": -0.91, "pegRatio": 0.3, "enterpriseToRevenue": 855.168, "enterpriseToEbitda": -0.266, "52WeekChange": -0.359375, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "LYEL", "underlyingSymbol": "LYEL", "shortName": "Lyell Immunopharma, Inc.", "longName": "Lyell Immunopharma, Inc.", "firstTradeDateEpochUtc": 1623936600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c5ad7970-8aa2-3c85-a7aa-1e907d8cc7ab", "messageBoardId": "finmb_590661061", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.05, "targetHighPrice": 9.0, "targetLowPrice": 4.0, "targetMeanPrice": 6.33, "targetMedianPrice": 6.0, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 526300000, "totalCashPerShare": 2.064, "ebitda": -218286000, "totalDebt": 61826000, "quickRatio": 16.267, "currentRatio": 16.511, "totalRevenue": 68000, "debtToEquity": 10.25, "returnOnAssets": -0.18935, "returnOnEquity": -0.32926, "freeCashflow": -84199128, "operatingCashflow": -159498000, "revenueGrowth": -0.954, "grossMargins": 1.0, "operatingMargins": -18530.0, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]